
Pfizer’s IBRANCE Wins FDA Approval for Frontline Maintenance in HR+, HER2+ Metastatic Breast Cancer
Pfizer’s IBRANCE Wins FDA Approval in HR+/HER2+ Metastatic Breast Cancer, Expanding CDK4/6 Use Into New Maintenance Setting Pfizer has secured a significant new U.S. regulatory milestone for IBRANCE (palbociclib), with…












